MATCH SIZE AND QUANTITY
Build your comparison.
Choose a labeled amount and selection to load matching prices.
Solution Peptides
153 products · 275 listings
Daily snapshot · inspect sources
Product comparison
Ipamorelin Atomized Solution Kit prices
Compare Ipamorelin Atomized Solution Kit listings by strength, selection and supplier. Inspect the original source behind each price.
1suppliers represented
1source-linked listings
0strengths available
GO BEYOND THE PRICE
Track it. Plan it. Inspect it.
Select a strength and selection above to view price history, save a price watch or add it to your basket.
DOCUMENTATION PASSPORTS
Reports and batch records
Inspect the source report, recorded lot and document access. A report link does not confirm the batch currently shipping.
Loading documentation records…
Listed amounts and selections
Comparable quantities are not established for these source-defined selections. Inspect the original listing before comparing.
Reported quantities in this family: not established. Counts and units must be matched to the exact listing.
Compare the exact selection
Choose the labeled amount per unit and quantity before comparing. A single unit and a multipack have different upfront prices. Keep product format and exact recipe consistent; similar names do not establish equivalent products.
Follow the original listing to check its quantity, availability and current price. 1 listing in this family have incomplete quantity details and receive no inferred per-mg price.
Suppliers with Ipamorelin Atomized Solution Kit listings
1 profilesSources and comparison limits
1 listing from direct supplier captures. Capture and import dates record when data was obtained; they do not guarantee the supplier’s current price or stock.
Listings include out-of-stock and unconfirmed-stock records. Inclusion does not certify a supplier, a batch or a product. Read how matching and source dates work.
Explore more selection listings
FROM PEPTIDES CALCULATOR
About Ipamorelin
Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile
Ipamorelin (NNC 26-0161) is a synthetic five-residue peptide developed by Novo Nordisk in the 1990s that triggers growth hormone release through the ghrelin receptor without the cortisol, ACTH or prolactin rise seen with earlier GHRPs. Human exposure comes from a 40-volunteer intravenous pharmacokinetic study and a 117-patient phase 2 trial run by Helsinn for post-operative ileus, which was safe but did not beat placebo, after which clinical development stopped. It has no approval anywhere, is prohibited by WADA, and in October 2024 the FDA's Pharmacy Compounding Advisory Committee voted 12 to 0 against adding either the free base or the acetate to the list of substances that may be compounded; it is nonetheless still prescribed off-label through compounding pharmacies and telehealth, usually at bedtime and often combined with the GHRH analog CJC-1295 without DAC.
- Formula
- C38 H49 N9 O5
- Molar mass
- 711.9 g/mol
- CAS number
- 170851-70-4
- Amino acids
- 5
Research evidence described in the source
Selective secretagogue profile
The foundational study showed GH release with less ACTH/cortisol response in animal models.
Early pharmacokinetic/pharmacodynamic work
Healthy-volunteer studies characterized concentration and GH response.
Unsuccessful ileus development
Phase 2 programs did not show meaningful improvement over placebo and development stopped.
Limitations noted in the source
- Short-term GH release is a biomarker, not evidence of body-composition or recovery benefit.
- Long-term metabolic, neoplastic, and endocrine safety is not established for wellness use.
- A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
- Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
Publications and references linked by the source
- pubchem.ncbi.nlm.nih.gov/compound/9831659
- link.springer.com/article/10.1023/A:1018955126402
- pubmed.ncbi.nlm.nih.gov/25331030/
- clinicaltrials.gov/study/NCT00672074
- www.fda.gov/advisory-committees/advisory-committee-calendar/october-29-2024-meeting-pharmacy-compounding-advisory-committee-10292024
- pubmed.ncbi.nlm.nih.gov/9849822/
- pubmed.ncbi.nlm.nih.gov/10373343/
- pubmed.ncbi.nlm.nih.gov/11735244/
Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.